Join us at the 2025 Cutting Edge of Transplantation (CEoT) – Transforming Tomorrow: Leading the Way in Organ Transplantation Modernization – from February 27 to March 1 in Scottsdale, AZ. Register today to be part of the future of transplantation.

Can't make the live meeting? The livestream is available for purchase. Don't miss out on expert insights and cutting-edge discussions from CEoT 2025. Get access to the livestream and stay up-to-date on the latest in transplant modernization – wherever you are. Secure your spot today!
 

The Fellow of the American Society of Transplantation (FAST) designation application is now open to all members who meet the eligibility criteria. Don't miss out on joining this prestigious program and be recognized for your contributions to transplantation!

For a limited time, the AST is offering an exclusive membership discount to transplant trainees. We're on a mission to help trainees boost their careers using the AST's benefits.

Through March 31, 2025, trainees can join the AST for just $60. To join with this promotion, you must qualify as a transplant trainee and be approved for membership. To receive the discount, use code TRAINEE2025.

Many members have inquired about the AST's role, engagement, and impact in addressing the ongoing and quite-fluid HHS-HRSA OPTN modernization process. Rest assured that your Society has been, and continues to be, at the table with HHS, HRSA, Congress, patients, and the stakeholder community from day one. The AST has worked diligently from the very beginning to strategically position the Society to keep the door open for engaging our government partners and all stakeholders throughout the modernization initiative.

The AST has submitted a letter to HHS Secretary Robert F. Kennedy, Jr., urging the administration to reconsider proposed NIH funding reductions that could hinder critical transplant research. Cutting support for essential infrastructure may slow advancements in organ availability, transplant survival, and innovative treatments. Read our full letter to learn more.

The AST is pleased to announce its call for nominations for the 2025 Achievement Awards.

Each year, the AST honors its members’ accomplishments and contributions to the field of transplantation through the Achievement Awards. Members are recognized at different levels of their careers with Basic Science Awards, Clinical Science Awards, and Distinguished Career Awards. Nominate a colleague today!

The AST developed a survey aimed at soliciting your perspectives on legislative and regulatory issues that significantly influence both patient care and professional practice. Our goal is to establish a platform for our membership to share their invaluable ideas and perspectives and actively engage with the Public Policy Committee and AST leadership. We look forward to your input as we navigate the dynamics of our ever-evolving landscape of transplant care and practice.

Solid organ transplant (SOT) recipients were excluded from clinical trials evaluating the efficacy of COVID-19 vaccines. There is uncertainty about the number of doses required to prevent life-threatening infection, as well as uncertainty in the optimal vaccine type and their durability. Our objectives were to provide recommendations on the number of COVID-19 vaccination doses, type of vaccine, dose of vaccine administered, and timing of vaccination in SOT recipients.

Pediatric solid organ transplantation is a complex process including a tightly orchestrated medication regimen, essential for prevention of infection, rejection, graft failure, and mortality. Pharmacogenomic (PGx) testing tailors medication therapy to the individual patient, focusing on safety, efficacy, and avoidance of adverse effects. Implementation of PGx panel results into clinical practice for pediatric transplant patients has not been evaluated.

This phase 3 multicenter, randomized, controlled clinical trial evaluated investigational cellular product (MDR-101) to produce immune tolerance vs standard of care, in kidney transplant recipients. Adult recipients of kidneys from 2-haplotype human leukocyte antigen-matched living siblings were randomized 2:1 to treatment (n = 20) or control (n = 10). The MDR-101 product was from the same kidney donor. Treatment recipients received a nonmyeloablative conditioning protocol with rabbit-antithymocyte globulin and low-dose total lymphoid irradiation (10 fractions). MDR-101 was infused (day 11).

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are frequently prescribed for T2DM control, with additional efficacy in congestive heart failure therapy and preserving renal function in CKD. Despite their potential to mitigate comorbidities, prescribing SGLT2 inhibitors following solid organ transplantation has been limited due to safety concerns regarding infection, renal function, and diabetic ketoacidosis.